DEEP SEQUENCING SHOWS THAT THE PRESENCE OF HBV BCP/PC VARIANTS REDUCES THE RATE OF HBSAG LOSS AMONG HBEAG-POSITIVE CHB PATIENTS TREATED WITH LONG-TERM TENOFOVIR DF THERAPY

Littlejohn M1, Yuen L1, Wong D1,2, Bayliss J1, Rosenberg G1, Jackson K1, Sozzi V1, Edwards R1, Gaggar A3, Kitrinos K3, Subramanian M3, Marcellin P4, Buti M5, Janssen H6,7, Gane E8, Thompson A2, Locarnini S1, Revill P1.

1Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
2Department of Gastroenterology, St. Vincent’s Hospital, Melbourne, Australia
3Gilead Sciences, Foster City, California, USA
4Hôpital Beaujon, University of Paris, Clichy, France
5Liver Unit, Valle d’Hebron (Ciberehd) University Hospital, Barcelona, Spain
6Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Canada
7Department of Gastroenterology and Hepatology, Erasmus MC University Hospital, Rotterdam, The Netherlands
8Auckland City Hospital, Auckland, New Zealand

Background: HBsAg loss, or functional cure, is now an important treatment endpoint for novel antiviral agents in clinical development however this is a rare event. Basal core promoter (BCP) and precore (PC) variants are immune escape variants selected during the development of HBeAg-negative CHB. We hypothesized that the presence of BCP/PC variants will reduce the probability of HBsAg loss during long-term NA therapy, and that conversely, individuals with WT virus would be most likely to achieve HBsAg loss.

Methods: GS-US-174-0103 evaluated the efficacy of tenofovir for the treatment of HBeAg-positive CHB. We used next generation sequencing (NGS) to identify the presence of BCP and PC variants at baseline in this study population (detection threshold 1%). We tested for an association between the presence of BCP/PC variants and HBsAg loss at week 192, adjusting for relevant co-variables including age, gender, HBV genotype, HBV DNA levels, HBsAg levels and HBeAg levels.

Results: Baseline serum samples from 157 CHB patients were analyzed by NGS. BCP/PC variants were common and presence varied by genotype. HBsAg loss was more common in the presence of WT vs. BCP/PC variants (41% vs. 3%, P<0001). The utility of BCP/PC sequence for predicting HBsAg loss was most useful among individuals with Gt A and D HBV (Gt A, HBsAg loss 50% vs. 8% for WT vs. BCP/PC; Gt D, 40% vs. 3%; P < 0.05). Only 1 case of HBsAg loss was observed in individuals with Gt B/C HBV, with BCP/PC variants detected in almost all individuals. The presence of WT virus was independently associated with HBsAg loss in multivariable models.

Conclusion: Patients with detectable BCP/PC mutants, even at low frequency using NGS, have a lower probability of HBsAg loss. Strategies to achieve functional cure of HBV infection through antiviral therapy should consider stratifying patients according to BCP/PC sequence.

Disclosure of Interest: This research was funded by Gilead Sciences.